Background. The majority of patients with end-stage renal disease on dialysis are
hyperphosphataemic. Lanthanum carbonate has been shown to be a highly effective …

Background. Hyperphosphataemia in dialysis patients is associated with significant
morbidity. We assessed the ability of lanthanum carbonate to control phosphate levels in …

Background Lanthanum carbonate is a highly effective phosphate binder with significant
potential as a treatment for hyperphosphatemia in patients with end-stage renal disease …

Background: Lanthanum carbonate, a new phosphate binder, is effective in reducing serum
phosphorus levels in patients with end-stage renal disease. A 1-year extension study to two …

BACKGROUND:: Lanthanum carbonate is a novel, non-calcium, non-aluminum phosphate
binder under evaluation for the treatment of hyperphosphatemia in end-stage renal disease …

Aims: No conventional phosphate binder is entirely satisfactory for the treatment of
hyperphosphatemia in patients with end-stage renal disease (ESRD). Consequently, there …

Background: Control of serum phosphate over the long term is essential in patients with end-
stage renal disease. Six-month and 2-year extensions to a 6-month study evaluated the long …

Aluminium-or calcium-based phosphate-binding agents traditionally have been used to treat
hyperphosphataemia in patients with end-stage renal disease. Although these agents …

Abstract Background/Aims: Hyperphosphatemia is an important clinical consequence of
renal failure, and its multiple adverse systemic effects are associated with significantly …

Abstract▴ Lanthanum carbonate is a novel, non-aluminium, non-calcium phosphate binding
agent that forms a water-insoluble compound, lanthanum phosphate, in the gut.▴ …